Inflammatory and Innate Immune Responses in Dengue Infection Protection versus Disease Induction by Costa, Vivian Vasconcelos et al.
The American Journal of Pathology, Vol. 182, No. 6, June 2013
AS
IP
20
13
AJ
P
CM
E P
rog
ramajp.amjpathol.orgREVIEW
Inﬂammatory and Innate Immune Responses in Dengue
Infection
Protection versus Disease Induction
Vivian Vasconcelos Costa,*y Caio Tavares Fagundes,*y Danielle G. Souza,*y and Mauro Martins Teixeira*From the Department of Biochemistry and Immunology* and the Laboratory of Microorganism/Host Interaction,y Department of Microbiology, Institute of
Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
CME Accreditation Statement: This activity (“ASIP 2013 AJP CME Program in Pathogenesis”) has been planned and implemented in accordance with the Essential Areas and
policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Society for Clinical Pathology (ASCP) and the
American Society for Investigative Pathology (ASIP). ASCP is accredited by the ACCME to provide continuing medical education for physicians.
The ASCP designates this journal-based CME activity (“ASIP 2013 AJP CME Program in Pathogenesis”) for a maximum of 48 AMA PRA Category 1 Credit(s). Physicians
should only claim credit commensurate with the extent of their participation in the activity.
CME Disclosures: The authors of this article and the planning committee members and staff have no relevant ﬁnancial relationships with commercial interests to disclose.Accepted for publicationC
P
hFebruary 5, 2013.
Address correspondence to
Mauro Martins Teixeira, Ph.D.,
Departamento de Bioquímica e
Imunologia, Instituto de Ciên-
cias Biológicas, Universidade
Federal de Minas Gerais, Av
Antônio Carlos, 6627 e Pam-
pulha, 31270-901, Belo Hori-
zonte, MG, Brazil. E-mail:
mmtex@icb.ufmg.br.opyright ª 2013 American Society for Inve
ublished by Elsevier Inc. All rights reserved
ttp://dx.doi.org/10.1016/j.ajpath.2013.02.027Dengue disease is a mosquito-borne viral disease of expanding geographical range and incidence. Infection
by one of the four serotypes of dengue virus induces a spectrum of disease manifestations, ranging from
asymptomatic to life-threatening Dengue hemorrhagic fever/dengue shock syndrome. Many efforts have
been made to elucidate several aspects of dengue viruseinduced disease, but the pathogenesis of disease is
complex and remains unclear. Understanding the mechanisms involved in the early stages of infection is
crucial to determine and develop safe therapeutics to prevent the severe outcomes of disease without
interfering with control of infection. In this review, we discuss the dual role of the innate and inﬂammatory
pathways activated during dengue disease in mediating both protection and exacerbation of disease. We
show that somemediators involved ineachof these responsesdiffer substantially, suggesting that interfering
in disease-associated immune pathwaysmay represent a potential therapeutic opportunity for the treatment
of severe dengue. (Am J Pathol 2013, 182: 1950e1961; http://dx.doi.org/10.1016/j.ajpath.2013.02.027)Supported by grants from the Instituto Nacional de Ciência e Tecnologia em
Dengue and PRONEX in Dengue funded by Conselho Nacional de Desen-
volvimento Cientiﬁco e Tecnologico (CNPq), Fundação de Amparo a Pesquisa
do Estado de Minas Gerais (FAPEMIG), and the Brazilian Ministry of Health.
Current address of C.T.F., Trinity College Dublin, Dublin, Ireland.Dengue is a spectrum of disease caused by one of the four
serotypes of the most prevalent arthropod-borne virus that
affect humans today, dengue viruses (DENV). The four
DENV serotypes (DENV-1 to -4) belong to the Flaviviridae
family and circulate concomitantly in different regions of
the world, covering approximately 100 countries in tropical
and subtropical areas of the globe, with potential for further
spread. Worldwide, it is estimated that 2.5 billion people are
at risk of infection, with occurrence of >50 million infec-
tions each year, including 50,000 hospitalizations of patients
with severe cases, mainly among children, with the case
fatality rate exceeding 5% in some areas.1,2
Most DENV infections are clinically unapparent. The
traditional World Health Organization classiﬁcation includesstigative Pathology.
.two major entities: dengue fever (DF) and dengue hemor-
rhagic fever/dengue shock syndrome (DHF/DSS).3 DF is
deﬁned as a self-limited though debilitating febrile illness,
accompanied by a combination of nonspeciﬁc symptoms,
including headache, retro-orbital pain, myalgia, and occa-
sionally hemorrhagic manifestations.3e5 The case deﬁnition
for DHF lists the presence of four criteria: fever, hemorrhagic
manifestations, thrombocytopenia (platelets counts of
Inﬂammatory Pathways in Dengue Disease100,000 cells/mm3), and evidence of plasma leakage (pleural
effusion, ascites, hemoconcentration 20%, or hypopro-
teinemia). In turn, DHF is divided into four grades (I to IV),
where grades III and IV are deﬁned as DSS with hypotensive
shock or narrow pulse pressure plus clinical signs of shock.3
A revised World Health Organization classiﬁcation of
dengue disease severity was performed recently and proved
to have much more sensitivity and speciﬁcity to identify
cases in need of heightened care. However, it is no longer as
speciﬁc for a particular pathogenic entity as was the tradi-
tional scheme, suggesting that its utility in pathophysiologic
and epidemiologic studies needs further investigation in
future research.3
Treatment of DF and DHF/DSS infection is largely
supportive.6 The large number of infected individuals, the
lack of clinical or laboratory markers that indicate which
patients will develop severe disease, and the lack of speciﬁc
treatment place an enormous burden on health systems of
low-income countries. Much interest has been placed in
understanding inﬂammatory and immune pathways that are
unleashed during host response to infection. It has been
suggested that mechanisms of protection against infection
may differ substantially from those associated with disease
progression, indicating that this difference may be exploited
for the development of novel therapeutic strategies against
dengue infection.5,7,8 We describe some of the mechanisms
associated with protection against infection and those
associated with severe disease evolution in DENV infection.
Pathophysiologic Aspects of Dengue Disease
A common major technical barrier in understanding the
pathogenesis of DENV infection is the absence of a suitable
animal model that mimics dengue disease, especially the
severe forms of disease (DHF/DSS).5,9 However, several
animal models of DENV infection have been described, are
currently available, and have been extensively reviewed
elsewhere.5,9,10 Table 1 summarizes the features and appli-
cability of the most common mouse models described. As in
any other area of biomedical research, these models have
advantages and disadvantages but clearly contribute to the
understanding of dengue infection, including immunopa-
thogenesis and preclinical testing of antiviral drugs and
vaccines. It is very unlikely that a single experimental model
will take into account all aspects of this complex human
disease. Therefore, knowledge in the ﬁeld must come from
adequate interpretation of data from current animal models,
in vitro experiments with immune cells, and clinical and
epidemiologic studies.
The pathogenesis of DENV-induced disease involves
a complex interplay of viral and host factors in the context of
the history of the patient. Risk factors for severe disease
include age, viral serotype and genotype, and the genetic
background of the host.2,11,12 Differences in virulence among
viral strains and especially among virus genotypes have been
found to play an important role in disease outcome. ForThe American Journal of Pathology - ajp.amjpathol.orgexample, DENV-3 genotype III, which includes isolates from
East Africa, South Asia, and Latin America, has been asso-
ciated with an increase in DHF/DSS in these regions.13,14
These studies indicate that certain viruses may cause more
severe disease in the population. However, mechanisms
explaining the higher proportions of severe dengue disease
manifestation during infection with these viral genotypes are
still obscure. They have been reviewed elsewhere.15
Most dengue cases reported are asymptomatic, and
apparent disease due to dengue infection represents <10%
of all symptomatic reported cases.4 The incidence of severe
disease (DHF/DSS) varies signiﬁcantly between primary
and secondary DENV infections,4 and observational studies
demonstrate that DHF/DSS occurs predominantly either in
individuals with secondary heterologous DENV infections
or in infants with primary DENV infections born from
dengue immune mothers.6,9,16 Epidemiologic and serologic
studies performed in Thailand and Cuba are good examples
of the importance of heterologous secondary infections as
a risk factor for DHF/DSS development and fatal cases. For
example, Thai data of DENV infections in children <15
years of age demonstrated that just 0.18% of primary
infected children manifested DHF/DSS, whereas 2% of
secondary infected children developed severe disease
manifestation.4 Similarly, Guzmán et al17 found that during
a 1997 outbreak in Santiago de Cuba, there were an adjusted
5208 laboratory-conﬁrmed dengue cases, with 202 of the
205 DHF/DSS cases (98.5%) and 4608 of the 5003 dengue
fever cases (92.1%) from secondary dengue infections. Only
3% of 13,116 primary infections cases caused apparent
symptoms.17 The sensitizing infection for DHF/DSS cases
in the DENV-2 epidemic in 1997 was the DENV-1 serotype
virus, which was transmitted in 1977 to 1979.18 These data
suggest that a prior dengue infection may set the stage for
a more deadly infection by a different serotype in a few
years’ time.
Several theories have been raised to explain the obser-
vation that more severe disease occurs in the context of
secondary infections. Most theories suggest that the immune
status of the patient is related to disease progression. One of
them, the antibody-dependent enhancement theory, postu-
lates that after an initial period of cross-reactive protection,
antibodies from a primary infection remain cross-reactive
with other DENV serotypes but have waned to non-
neutralizing levels. These nonneutralizing antibodies could
then lead to viral internalization via the Fc receptors and
increase virus replication into phagocytic cells, what is
accompanied by massive release of soluble factors that
could account for the increased vascular permeability and
hemostatic disorder found in severe cases.6,16 In accordance,
Dejnirattisai et al19 have demonstrated that although most
monoclonal antibodies against antieE protein neutralized
DENV effectively, a large proportion of the human antibody
repertoire directed against the precursor membrane protein,
which is present on immature virus particles, failed to do so,
leading to enhanced viral infection and replication in Fc1951
Table 1 Features of Mouse Models of Dengue Virus Infection Used for Preclinical Studies
Mice strains Features Advantages Disadvantages Applicability
Mouse-human
chimeras
(humanized mice)
SCID mice, NOD/
SCID mice, RAG2/
mice, and NSG mice
Mice reconstituted with
human hematopoietic
stem cells (from umbilical
cord blood or fetal cells)
or a variety of dengue
virusesusceptible tumor
cells infected with
relevant clinical isolates
of dengue virus
Mice develop functional
human immune system,
including some level of
adaptive immunity;
infection of human cells
lineages; study of human
response to infection.
Only mild disease
manifestation (DF)
Study of DF pathogenesis,
human cell virus tropism,
virulence screening of
dengue virus (including
differences in
genotypes), and vaccine
studies evaluating virus
attenuation in vivo
Immunocompromised
mice AG129 (mice
lacking both IFN-a/b
and IFN-g
receptors)
Mice infected with clinical
isolates of dengue virus
or with mosquito cell/
mouse adapted dengue
virus isolates; higher
viremia
Support replication of
relevant dengue virus
clinical isolates; mice
develop marked viremia
(viremia model),
antibody-dependent
enhancement model
Absence of critical
components of host
antiviral system;
inadequate for studies
evaluating immune
responses to infection
and severe disease
pathogenesis; occurrence
of paralysis and lethal
encephalitis
Investigate tissue and
cellular tropism of
dengue virus, antiviral
drugs screening
Immunocompetent
mice BALB/c and
C57BL/6j strains
Mice with intact immune
system infected with
mouse-adapted dengue
virus isolate
Mice develop the major
clinical manifestations of
human severe dengue
virus infection (pain,
thrombocytopenia,
hemoconcentration,
increased vascular
permeability,
hypotension, increased
levels of cytokines, and
chemokines, tissue
hemorrhage, viremia, and
recovery of viral load in
target organs of infection)
Single strains of dengue
virus 2 or 3 that were
adapted by multiple
passages in mice;
modification of the virus
to the murine host may
involve pathologic
mechanisms different to
that of the original virus
in humans; severe
disease occurs in primary
infection
Study of severe dengue
disease pathogenesis,
cell virus tropism, and
host inflammatory and
immune responses to
infection
Reviewed in Fagundes et al,5 Rothman,9 and Zompi and Harris.10
DF, dengue fever; NOD, nonobese diabetic; NSG, nonobese several combined immunodeﬁciency g; SCID, severe combined immunodeﬁciency.
Costa et alreceptorebearing cells. Experimental infections in mice
have also brought support to this theory,20,21 and non-
neutralizing antibodies also drive higher virus loads in
nonhuman primates.22,23 Therefore, subneutralizing levels
of antibodies may contribute to the development of severe
dengue diseases during secondary infections. A distinct but
complementary theory of immunopathology involves reac-
tivation of cross-reactive memory B and T cells speciﬁc for
the previous rather than the current DENV infection, re-
sulting in delayed viral clearance and/or increased cytokine
secretion along with increased apoptosis of both infected
and uninfected bystander cells.9 There is immunologic
evidence that this phenomenon of original antigenic sin may
occur during secondary DENV infections.9,24,25
However, although in smaller rates, primary DENV
infection may lead to severe disease manifestation.4 This can
be exempliﬁed by the DENV-3 introduction in Rio de
Janeiro, Brazil, in 2002, which was responsible for one of the
most severe epidemics in the state’s history in terms of the1952highest number of reported cases, the severity of clinical
manifestations, and the number of conﬁrmed deaths.26
During this epidemic, 56% of the conﬁrmed DENV-3 non-
fatal cases analyzed were due to primary infection. Further-
more, 54% of the lethal cases analyzed were classiﬁed
as primary DENV-3 infections,26 demonstrating that pri-
mary infections may cause severe disease. To explain ﬁnd-
ings such as these, a theory claims that severe dengue disease
manifestation does not necessarily depend on a secondary
infection but rather on a combination of viral load, strain
virulence, and host immune response.27 Hence, ﬁeld studies
have noted higher levels of viremia in DHF patients, which
supports the assertion that increased viral replication is
associated with more severe disease.28e31 In addition, there is
some correlation among higher viral titers or the infecting
virus serotype/genotype with the occurrence of DHF/DSS,
independently of whether the infection is primary or
secondary.28,32,33 These ﬁndings suggest that evolution to
severe disease during primary DENV infections is favored byajp.amjpathol.org - The American Journal of Pathology
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enhanced production of mediators of inﬂammation.
Of note, there seems to be a consensus among these
theories: whether involving primary or secondary infections,
an exacerbated host response is believed to play a direct
role in the pathogenesis of severe dengue disease.9,27,34 It
has been suggested that DHF/DSS manifests in the context
of ampliﬁed production of cytokinesda cytokine stormd
that ultimately targets the vascular endothelium and even-
tually leads to transient increase in vascular permeability,
occurrence of hemorrhagic manifestations, hemoconcentra-
tion, and, in some cases, development of intractable shock,
resulting in death.9,27,34
Therefore, it seems that excessive inﬂammation contrib-
utes to the pathogenesis of severe dengue disease.11,35
Hence, although elevated levels of proinﬂammatory cyto-
kines and chemokines occur in patients with DF, most of
them are found in higher levels in patients experiencing
severe dengue disease.36e39 For example, heightened levels
of tumor necrosis factor (TNF)-a, IL-6, IL-8, IL-10, che-
mokine ligand (CCL)-2, CCL-3, CXCL-8, CXCL-10, and
interferon (IFN)-g have been reported in patients with
severe dengue disease.9,39e44 Many of these cytokines have
already been linked to disease severity, including hepatic
dysfunction, hypotension, thrombocytopenia, and hemor-
rhagic shock.9 However, it is not clearly understood how
this massive cytokine production is induced and eventually
controlled. Nevertheless, the latter ﬁndings suggest that
severe dengue disease relies on uncontrolled immune cell
activation, increased proinﬂammatory mediator production,
and consequent endothelial cell dysfunction unleashed by
the virus and several immunopathologic mechanisms.
Innate Immune and Inﬂammatory Pathways
Activated during Dengue Disease: Protective
versus Pathologic Mediators
Pattern Recognition Receptors and Other Molecules
Involved in DENV Sensing
Langerhans cells, dermal cells, and interstitial dendritic cells
have long been proposed as initial targets for DENV
infection at the site of the mosquito bite.39,45 Viral antigens
have also been detected on monocytes, lymphocytes,
Kupffer cells, alveolar macrophages, and endothelial cells of
DENV-infected humans.46 Although the ability of these
cells to support DENV replication in vivo and the mecha-
nisms involved in viral tropism to them are yet to be
demonstrated, they are thought to mount the initial antiviral
responses at the ﬁrst stages of DENV infection. Host pattern
recognition receptors (PRRs) in these cells are responsible
for sensing viral proteins or nucleic acids. The endosomal
Toll-like receptors (TLRs)47 and the cytoplasmic receptor
family of DExD/H box RNA helicases [eg, retinoic acid
inducible gene I (RIG-I) and melanoma differentiation-
associated gene 5 (MDA5)]48 are the two most importantThe American Journal of Pathology - ajp.amjpathol.orgfamilies of sensors present in mammalian cells that are
implicated in detecting viral nucleic acids. On viral recog-
nition by these molecules, there is activation of two im-
portant families of transcriptional factors: the interferon
regulatory factors and the NF-kB. Both of these signaling
cascades activate the production of IFN-a/b and inﬂam-
matory cytokines that leads to activation of dendritic cells
and establishment of an antiviral response.49
Recently, several studies have demonstrated the impor-
tance of TLR3 in the recognition and restriction of DENV
replication in different cell lineages.50e52 TLR7 was also
demonstrated to be essential for DENV-induced production
of type I IFN in plasmacytoid dendritic cells.53 In addition,
administration of TLR3 and TLR7/8 agonists to rhesus
macaques enhanced antiviral mechanisms via increasing
inﬂammatory and humoral responses, leading to decreased
DENV replication during primary infection.54 The invol-
vement of RIG-I and MDA5 in DENV sensing has been
recognized through gene expression analysis.55 Interaction
of DENV with these receptors results in the activation of
a macromolecular signaling complex that stimulates inter-
feron regulatory factor 3 and NF-kB, which in turn induces
IFN-b promoter. In addition, experiments using single and
double RIG-I/MDA5edeﬁcient mouse ﬁbroblasts showed
that DENV triggers both of these responses.56 Also, early
detection of antibody-enhanced DENV infection via RNA
sensors, such as the RIG-I, by tissue-resident mast cells
culminated in production of type I interferons and rapid
production of chemokines, including CCL4, CCL5, and
CXCL10.57 In accordance, DENV infection of human brain
microvascular endothelial cells promoted an increase in the
production of type I IFN and proinﬂammatory cytokines,
which were abolished after RIG-I silencing,58 and mice
deﬁcient for the RIG-I/MDA5 adaptor IPS-1 present
delayed production of type I IFN in lymphoid tissues and
increased viral loads in the early phases of primary infec-
tion.59 Finally, Nasirudeen et al51 found that the RIG-I,
MDA5, and TLR3 sensors act synergistically to induce
IFN-b production and impair DENV replication in vitro.
Therefore, RIG-I, MDA5, and TLR3 sensors are the major
PRRs involved in recognition and mounting of innate res-
ponses to DENV infection.
Activation of these PRRs by DENV is thought to induce
a strong type I IFN response during human natural infections.
IFN-a is present at high levels for long periods in pediatric
patients after defervescence period.60 In addition, it was
demonstrated in mice that this IFNAR-dependent control of
DENV primary infection involved both STAT1-dependent
and STAT1-independent mechanism.61 The STAT1-
dependent pathway was demonstrated to be involved in the
control of initial steps of infection; however, the STAT1-
independent pathway was suggested to be involved in the
later antiviral mechanisms that control virus propagation and
disease control.61 Interestingly, DENV has evolved mecha-
nisms to subvert antiviral response induced by type I IFNs.
Hence, expression of NS2A, NS4A, and NS4B in cells was1953
Costa et alcapable of enhancing replication of IFN-sensitive viruses in
the presence of exogenous IFN-a/b stimulation, indicating
that these proteins may block the effects of IFN-a/b before
infection.62 These studies have demonstrated that NS4B
blocks the JAK/STAT signaling induced by IFN-a/b through
inhibition of STAT1 phosphorylation and nuclear trans-
location.62 These data highlight the crucial importance of
type I IFN system in host response to DENV infection.
Despite the role of DENV-sensing receptors on the
development of protective responses on infection, it seems
that some other molecules involved in recognition of DENV
may unleash pathological host responses. For example, Chen
et al63 noted that the C-type lectin domain family 5 member A
(CLEC5A) directly interacts with the dengue virion, resulting
in stimulation of the release of proinﬂammatory cytokines.
Importantly, blockade of the CLEC5AeDENV interaction
suppressed the secretion of proinﬂammatory cytokines after
primary infection in vitro and in vivo. Moreover, treatment of
DENV-infected mice with anti-CLEC5A monoclonal anti-
bodies inhibited DENV-induced plasma leakage and vital-
organ hemorrhaging, culminating in reduced mortality after
infection by approximately 50% in STAT1-deﬁcient mice,
without interfering with host response to infection.63 Hence,
CLEC5A blockade did not interfere with the production of
type I IFNs by infected cells.63 These ﬁndings support the
concept that DENV recognition by CLEC5A induces proin-
ﬂammatory cytokine release and disease exacerbation during
infection. However, it remains to be shown whether CLEC5A
activation affects disease evolution in patients. A study
evaluating single-nucleotide polymorphisms in CLEC5A
could not ﬁnd any association between genetic variants of this
molecule and manifestation of DF or DHF in patients.64 In
addition, CLEC5A expression seems to be diminished in
dengue patients.65 Although these ﬁndings do not exclude the
possibility that CLEC5A activation may favor severe disease
evolution during DENV infection in humans, more extensive
clinical data are required to conﬁrm the importance of
CLEC5A in dengue pathogenesis. Future studies looking for
enhanced CLEC5A activation in dengue patients, for
example, evaluating DAP12 phosphorylation, along with an
association with proinﬂammatory cytokine production and
severe disease manifestationmay help to answer this question.
DENV-antibody complex recognition by host cells during
antibody-dependent enhancementemediated disease also
seems to unleash pathologic responses during infection. It
has been reported that ligation between DENV-antibody
complexes and FcR not only down-regulates TLR gene exp-
ression but also up-regulates negative regulators of the NF-kB
pathway, resulting in suppression of innate responses and
increased viral production.66 Importantly, the same phenom-
enon was seen in peripheral blood mononuclear cells of
secondary DHF/DSS patients but not in peripheral blood
mononuclear cells of DF patients. These results were sup-
ported by experiments with anti-FcgRI or anti-FcgRIIa anti-
bodies, which reduced viral production, up-regulated IFN-b
synthesis, and increased gene expression in the TLR-dependent1954signaling pathway.66 Therefore, recognition of DENVeanti-
body complexes impairs host protective responses to infection,
favoring viral replication and disease exacerbation.
Cytokines, Chemokines, and Leukocyte Populations
As stated, in addition to type I IFNs, PRR activation onDENV
infection mediates proinﬂammatory cytokine production. For
example, several studies have demonstrated enhanced levels
of TNF-a, IL-6, IL-8, CCL2, CCL3, CXCL10, and IFN-g in
primary and secondary DENV infection of humans9,38e44,60
or mice.20,21,67e69 Some of these cytokines may play essen-
tial protective roles during infection. This is the case with
IFN-g. Using murine immunocompetent models of primary
DENV infection, we have demonstrated that production of
IL-12 and IL-18 proinﬂammatory cytokines precedes IFN-g
release, and optimal IFN-g production relies on the combined
action of these two cytokines.68,69 For instance, Pacsa et al70
have reported that DF patients present elevated levels of IL-
12, whereas patients experiencing DHF grades III and IV
had nondetectable levels of this cytokine.70 In our experi-
mental settings, we demonstrated that IFN-g production is
essential for host resistance to primaryDENV infection in part
by controlling nitric oxide synthase 2emediated nitric oxide
production,68,69 a virustatic radical previously found to inhibit
DENV replication.71 Importantly, Gunther et al72 have
demonstrated in a human challengemodel of DENV infection
that only sustained IFN-g production was associated with
protection against fever and viremia during the acute phase of
illness.72 These data establish IFN-g as essential for host
control of DENV replication and resistance to infection. The
correlation between increased IFN-g production and higher
survival rates in DHF patients41 also supports this idea.
On the contrary, other proinﬂammatory cytokines seem to
play a pathologic role during host response to DENV infec-
tion. For example, increased levels of TNF-a have been
associated with severity of denguemanifestation in humans.40
T cells isolated from hospitalized patients with more severe
disease evolution produced higher amounts of TNF-a after
ex vivo stimulationwithDENVantigens.73 Findings inmurine
experimental models indicated that TNF-a blockade resulted
in prevention of primary74,75 and secondary20 infectionein-
duced lethality, and TNF-a action has been implicated in
increased vascular permeability after infection in experimental
settings.12 Altogether, these ﬁndings suggest that severe
disease may occur due to enhanced TNF-a production during
host response to infection.
Another cytokine found to have a deleterious role during
DENV infection is the macrophage migration inhibitory factor
(MIF). MIF concentrations are positively correlated with
severity in DENV infection.76,77 In addition, experimental
primary infection demonstrated that clinical disease was less
severe inMIF/mice, and they exhibited a signiﬁcant delay in
lethality.76 This reduction in all parameters of severity ofDENV
infection in MIF/ mice correlated with reduced proin-
ﬂammatory cytokine levels (such as TNF-a) and lower viralajp.amjpathol.org - The American Journal of Pathology
Inﬂammatory Pathways in Dengue Diseaseloads at the initial phases of infection.76 Therefore, elevated
production of the proinﬂammatory cytokines TNF-a and MIF
during host response to DENV infection seems to play a dele-
terious role, favoring manifestation of more severe disease.
The chemokine system also appears to have this dual
protective versus pathologic role during DENV infection.
It has been shown that CXCL10 production and CXCR3
activation improve host resistance during DENV infection.
CXCL10 seems to compete with DENV for their cellular
receptors, diminishing viral replication,41 and, importantly,
mice deﬁcient for CXCL10 of CXCR3 had impaired resis-
tance to primary infection, due to a defect in activation of
CD8þ T cell and NK cells.78 On the opposite direction,
clinical studies in endemic areas have described a correla-
tion between dengue disease outcome and levels of CCL3,
and CCL49,42 and CCL2 concentrations are intimately
related to hypotension, thrombocytopenia, and hemorrhagic
shock.42 Also, a link between CCL5 and DENV-induced
hepatic dysfunction has already been found.79 Further-
more, data from our group demonstrated that CCR2/ mice
showed reduced lethality rates after primary DENV infec-
tion, in parallel with diminished liver damage, lower pro-
duction of IL-6, and attenuation of leukocyte activation.80
In CCR4/ mice, lethality, hepatic damage, and systemic
inﬂammation were also markedly decreased. Despite
differences in disease presentation in CCR-deﬁcient mice,
there was no difference in viral load.80 In conclusion, these
data demonstrate that although CXCR3 seemed to mediate
protective host responses to DENV infection, activation of
CCR2 and CCR4 was mostly associated with the develop-
ment of disease rather than with protection to infection.
Cellular populations involved in protective or pathologic
host responses to DENV infection are still obscure. It is well
accepted that some of the activated cell populations during
DENV infectionmay be crucial for control of viral replication,
such as CD8þ T cells81; although in the context of secondary
infections, some clones of these populations may favor severe
disease evolution.9 We have recently reported that invariant
natural killer T (iNKT) cells play a critical role in the patho-
genesis of severe experimental dengue disease.82 Our data
demonstrated that, on primary DENV challenge of immuno-
competent mice, splenic and hepatic iNKT cells became
activated. In addition, C57BL/6 mice deﬁcient in iNKT cells
(Ja18/) were more resistant to lethal infection than were
wild-type animals, and the phenotype was reversed by adop-
tive transfer of iNKT cells to Ja18/ animals. Ja18/ mice
had decreased systemic and local inﬂammatory responses, less
liver injury, diminished vascular leak syndrome, and reduced
activation of natural killer cells and neutrophils on infection.
Of note, iNKT cell functions were not necessary for control of
primary DENV infection after either natural endogenous
activation or exogenous activation with the canonical iNKT
cell agonist a-galactosylceramide.82Whether iNKT cells play
such pathological role during clinical DENV settings remains
to be evaluated. Nevertheless, these data support the idea that,
in a similar way to what is found for viral sensors and solubleThe American Journal of Pathology - ajp.amjpathol.orgmediators, some cellular components activated during DENV
infection are related to disease progression rather than to
protection.
Protective versus Pathological Pathways during DENV
Infection: Their Effects on Vascular Endothelium and
Plasma Leakage
Plasma leakage is a hallmark of severe disease manifestation
(DHF/DSS) in DENV-infected patients and is thought to
contribute to the pathogenesis of disease.83 Effusions,
ascites, and gallbladder wall edema are commonly found in
DENV-infected patients around the time of defervescence
and correlate with disease severity.83e88 The endothelium is
the primary ﬂuid barrier of the vasculature, and DENV-
induced responses that result in edema and hemorrhage
are thought to ultimately cause changes in endothelial cell
barrier permeability.
Whether blocking vascular leak may result in improve-
ment of DHF/DSS outcome is still unknown. However, one
study in a mouse model of infection suggests that this may
be true. Groger et al89 demonstrated that FX06, a 28eamino
acid cleavage product of ﬁbrin that interacts with vascular
endothelial cadherin, reduced vascular leak and mortality in
an animal model of primary dengue infection. Animals
treated with FX06 (ﬁrst treatment on day 3 after infection)
had improved survival rates accompanied by reduced capi-
llary leak in the lung and the intestine, a marked reduction in
hemoconcentration, and lessﬁbrinogen consumption.Of note,
viral loads in serum, liver, and brain at day 7 after infection, the
peak of disease, did not differ between groups that received
FX06 or controls. The ability of FX06 to preserve endothelial
barriers was conﬁrmed in lipopolysaccharide-induced sys-
temic shock, and the authors have evaluated the mechanisms
involved in antipermeabilizing effects of FX06 in this model.
The protective effects were associated with prevention of
thrombin-induced stress ﬁber formation, myosin light chain
phosphorylation, and RhoA activation in endothelial cells.89
The molecular key for the protective effect of FX06 was the
src kinase Fyn, which is associated with vascular endothelial
cadherinecontaining junctions. After exposure to FX06, Fyn
dissociates from vascular endothelial cadherin and associates
with p190RhoGAP, an antagonist of RhoA activation.89
Although these pathways were not demonstrated in the
DENV infection model, these data suggest that inhibition of
plasma leakage development, via stabilization of endothelial
cell-cell contacts, may lead to a better outcome for dengue
severe disease, with no major impact on host control of
infection. However, there is no evidence of these premises in
clinical settings, which represents an interesting and valuable
subject for future research.
Of note, the increased vascular permeability during the
defervescence phase of dengue illness is usually found
without morphologic damage to the capillary endothelium.
Because of the paucity of structural damage to the vascu-
lature found in autopsy studies, it has been suggested that1955
Costa et alcirculating factors are primarily responsible for the occur-
rence of microvascular permeability during DENV infec-
tion.9,34,83 Therefore, mediators produced by leukocytes
during response to infection represent potential players in
enhanced plasma extravasation seen in severe cases of
DENV infection. Hence, cytokines and other inﬂammatory
mediators act on the endothelium, potentially altering normal
ﬂuid barrier functions of endothelial cells.11,34,90,91 Sup-
porting this hypothesis, Cardier et al92 have found that serum
samples obtained from patients in the acute phase of DENV-
infection induce activation of endothelial cells in a mecha-
nism that involves enhanced circulating TNF-a levels.92 This
study did not evaluate any permeabilizing property of the
serum samples of DENV-infected patients on the endothelial
cell monolayer, but this study supports the concept that
production of proinﬂammatory mediators during infection
will ultimately change activation status and function of the
endothelium, potentially favoring enhanced plasma leakage.
The deleterious role played byMIF duringDENV infection
seems to involve its permeabilizing effects on the endothe-
lium. In vitro studies have found that DENV infection of the
human hepatoma cell line induced MIF production and that
medium collected fromDENV-infected human hepatoma cell
line cells enhanced the permeability of the human endothelial
cell line, which was reduced in the presence of aMIF inhibitor
(ISO-1).77 Medium from DENV-infected MIF knockdown
human hepatoma cell line cells also presented diminished
permeabilizing effects in the endothelial cell monolayers.
Authors found that MIF interferes in the arrangement of tight
junction protein ZO-1 of the human endothelial cell line and
that the arrangement was partially recovered when cells were
treated with ISO-1 or PI3K/MEK-ERK/JNK signaling
pathway inhibitors.77 Of note, MIF-deﬁcient mice infected
with DENV-2 presented reduced hemoconcentration during
the disease, suggesting that MIF may mediate increased
plasma extravasation during in vivo infection.76 Therefore,
elevated production of the proinﬂammatory cytokine MIF
during host response to DENV infection seems to interfere in
endothelial barrier function, enhancing plasma extravasation
and favoring development of more severe disease.
Chemokines may also be involved in increased vascular
permeability found in severe dengue disease. As stated be-
fore, CCL2 concentrations are intimately related to hypo-
tension, thrombocytopenia, and hemorrhagic shock in
patients.42 Hence, Lee et al36 found higher levels of CCL2 in
the plasma of DHF patients when compared with DF patients
or patients infected with enterovirus-71.36 In addition, they
have reported that exposing monolayers of human umbilical
vein endothelial cells to the culture supernatant of DENV
2einfected human monocytes increased the permeability of
the cell monolayer, an event partially reversed by CCL2
neutralization. This seemed to involve disruption of endo-
thelial tight junctions through reorganization of protein
ZO-1.36 Although CCL2 correlates with disease severity in
patients42 andmice deﬁcient for the CCL2 receptor CCR2 are
protected from DENV-2einduced lethality,80 there is no1956in vivo evidence that CCL2 may modulate plasma extrava-
sation. Hence, CCR2-deﬁcient mice do not present any
improvement in hemoconcentration during the course of
DENV-2 infection.80 Therefore, the data involving endo-
thelial cells monolayers suggest that CCL2 may be involved
in DENVeinduced plasma leakage, a premise that deserve
further investigation in clinical and in vivo settings.
Besides the effects of cytokines and chemokines, leading
to increased vascular permeability, it was also demonstrated
that other molecules produced by DENV-infected leuko-
cytes can also play a role on the vascular endothelium.
Luplerdlop et al93 showed that DENV infection of immature
dendritic cells led to overproduction of soluble matrix
metalloproteinases 9 and 2 and that these enzymes were
capable of enhancing endothelial permeability of human
umbilical vein endothelial cell monolayer cells in vitro and
in a model of vascular permeability in vivo.93 Of note,
matrix metalloproteinase 9 production is enhanced in pa-
tients with DENV infection and is associated with severity
of disease.94 In another study, Ong et al95 demonstrated that
enhanced levels of high mobility group box 1 (HMGB1)
protein was detected after DENV infection of human
myelogenous leukemia cells (K562) and also from primary
peripheral blood monocytes and that HMGB1 was released
from DENV-infected K562 cells into the extracellular
milieu. They also demonstrated that application of DENV-
infected K562 cell culture supernatants to primary endo-
thelial cells induced vascular permeability in vitro in
a HMGB1-dependent manner.95 HMGB1 has also been
shown to be elevated in DENV-infected patients, with
higher circulating levels in those experiencing secondary
DENV infections.96 Therefore, the elevated levels of
HMGB1 and matrix metalloproteinase 9 could potentially
mediate the increase in plasma leakage during infection in
patients. These two reports suggest that mediators others
than cytokines and chemokines may be involved in en-
hanced plasma extravasation during severe dengue disease.
Although conclusive evidence of DENV infection of
endothelial cells in patients is lacking, DENV can clearly
infect human endothelial cell lines in vitro.11,58,92 DENV
antigens but not genome was detected in endothelial cells in
the liver sinusoids and the alveoli in human autopsy samples.46
In addition, in several recent studies, DENV antigens have
been detected in endothelial cells of infected mice.20,97 These
data suggest that DENV may infect endothelial cells and that
this cell population represents direct contributors to the
immune enhancement, capillary permeability, viremia, and
immune targeting of the endothelium during the pathogenesis
of the disease. Hence, DENV-infected endothelial cells
present high-level transcriptional and secretory responses of
chemokines, cytokines, and other inﬂammatorymediators that
are consistent with the immune-enhancing and permeability-
inducing responses observed in DENV patients.58,90
An example of the importance of endothelial function
during severe dengue disease was demonstrated by Srikiat-
khachorn et al.98 They have found that DENV suppressedajp.amjpathol.org - The American Journal of Pathology
Inﬂammatory Pathways in Dengue Diseasesoluble vascular endothelial growth factor 2 (VEGFR2)
production by endothelial cells but up-regulated surface
VEGFR2 expression and promoted response to VEGF
stimulation. These in vitro results were supported in vivo,
once plasma viral load in DENV-infected patients correlated
with the degree of decline in plasma soluble VEGFR2.
Importantly, the severity of plasma leakage in DENV-
infected patients inversely correlates with plasma levels of
soluble VEGFR2.98 These results suggest that vascular
endothelial growth factor regulates vascular permeability and
its activity is controlled by binding to soluble VEGFR2.
Dengue viruseinduced changes in surface and soluble
VEGFR2 expression may be an important mechanism of
plasma leakage in DHF,98 although it is not clear whether
such effects are due to direct endothelial cell infection by
DENV or involve an indirect mechanism.
Interestingly, type I IFNs may be important for preventing
severe dengue disease also because of their effects on endo-
thelium. DENV replication in endothelial cells is dependent
of suppression of early IFN-b responses by DENV.91 In IFNFigure 1 Mechanisms involved in protection and disease during host response
endothelial compartments trigger several immune mechanisms and inﬂammatory
protection from infection such as that controlled by activation of the receptors TLR
(partly dependent on STAT1 activation). In addition, the production of IFN-g, ind
nitric oxide. Other protective mechanisms unleashed by DENV infection involve
secondary infections), CD8 T-cell activation, and CXCR3-mediated recruitment o
ultimately leads to exacerbation of disease (left). For example, activation of
proinﬂammatory mediators. Some of these molecules seem to play negligible role
therapeutic intervention. Hence, inhibition of the cytokines TNF-a and MIF; of act
cells results in reduced disease severity after DENV infection, with no alteration in
these pathways interferes with host antiviral responses, as demonstrated by the
complexes (arrow). As a ﬁnal target, these molecules with a pathologic role dur
barrier, enhancing plasma extravasation (represented by the dashed endothelia
disease. This is exempliﬁed in the ﬁgure by the effects of matrix metalloprote
Interestingly, some of the protective antiviral molecules exert antipermeabilizing
The American Journal of Pathology - ajp.amjpathol.orgreceptoredeﬁcient mice, there is substantial infection of
endothelial cell compartment by mouse-adapted DENV20,99
and subneutralizing antibodies enhance infection, especially
of liver sinusoidal endothelial cells in these mice models of
infection.20 Importantly, in addition to controlling viral
replication, it has been found that type I IFN response may
mediate protective effects against cytokine-induced increased
permeability of endothelial cells.100 Hence, autocrine type I
IFN production suppressed TNF-aeinduced hyperperme-
ability of DENV-infected endothelial cell monolayers. In
addition, at later time points of infection of endothelial cells, at
a moment when type I IFN production is suppressed, cell
monolayers are more susceptible to TNF-aeinduced perme-
ability, and addition of exogenous type I IFN prevented this
increased permeability of endothelial cell monolayers to
macromolecules.100 Of note, type I IFNs have been reported
to stabilize the vascular barrier in several conditions.101e103
Finally, Gomez and Reich104 found a proliferative effect of
type I IFNs on primary human endothelial cells in a STAT-
dependent manner. The authors suggest that through suchto DENV infection. On DENV infection of permissive cells, host immune and
pathways to control viral replication (right). Some pathways are critical for
3, RIG-I, and MDA5, which mediate type I IFNemediated antiviral responses
uced by IL-12 and IL-18, controls the production of the virucide metabolite
the production of neutralizing antibodies (especially in the context of
f leukocytes. However, several mediators produced during host response
FcgRs by antibodyeDENV complexes leads to exacerbated production of
s in the control of infection and, therefore, consist of potential targets for
ivation of PAFR, CCR2 receptor, and CCR4 receptor; and of activation of iNKT
viral clearance. Importantly, it has been reported that activation of some of
inhibition of TLR signaling by the activation of FcgRs by antibody-DENV
ing infection seem to act directly or indirectly in the endothelial vascular
l cells) during of infection and favoring manifestation of severe dengue
inase 9, HMGB1, MIF, CCL2, and activation of PAFR on endothelial cells.
effects in the endothelium, as demonstrated for type I IFNs.
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Costa et alproliferative effects on endothelium, IFNs may support the
physical barrier between the vascular circulation and the
underlying tissue, preventing the occurrence of plasma
leakage.104 Altogether, these data suggest that type I IFNs
protect against increased vascular permeability during infec-
tion, aside from controlling viral replication. It is possible that
other molecules found to be protective against DENV infec-
tion may possess antipermeabilizing effects in addition to
their antiviral activities, presenting, therefore, a dual mecha-
nism by which they may avoid evolution to severe disease
manifestation.
Targeting Mediators Involved in Progression of Disease
after DENV Infection
From the ﬁndings described, we conclude that in DENV
infection, the host cell populations (including both immune
and/or endothelial cells) trigger several immune mechanisms
and inﬂammatory pathways to control viral replication. Some
pathways are critical for protection from infection, such as the
IFN system (including type I IFNs and IFN-g). On the contrary,
several mediators produced during host response ultimately
lead to exacerbation of disease (such as TNF-a and MIF)
(Figure 1). Whatever the mechanism, these mediators secreted
during the infection ultimately target the vascular endothelium,
affecting the development of vascular permeability and severe
diseasemanifestation.Someof the lattermolecules seemtoplay
negligible roles in the control of infection and are, therefore,
potential targets for therapeutic intervention. It is possible that
a decrease in the production or action of such molecules may
decrease dengue disease severity in humans.
A molecule that seems to be a useful as therapeutic target
in the context of the dengue is the platelet-activating factor
receptor (PAFR). PAF is released from macrophages ob-
tained from patients previously infected with DENV-1
compared with controls.105 Importantly, our group has
found a novel role for the PAFR in the pathogenesis of severe
dengue.67 Using immunocompetent mice, we found that the
course of primaryDENV infectionwas less severe inPAFR/
mice. Administration of a PAFR antagonist, UK-74,505,
after disease manifestation (even 5 days after infection)
drastically inhibited the major manifestations of the severe
dengue disease, including thrombocytopenia, hemoconcen-
tration, plasma extravasation, hypotension, and lethality.
Mechanistically, blockade of PAFR decreased production of
TNF-a and other proinﬂammatory cytokines after infection,
suggesting that PAF/PAFR interactions on leukocytes and
other cell populations could potentially lead to the cytokine
storm and enhanced inﬂammatory response seen during
experimental DENV-2 virus infection.67 In addition, there
was diminished vascular permeability and hypotension
in UK-74,505etreated and PAFR-deﬁcient mice infected
with DENV.67 It is well known that PAF exerts potent
permeabilizing effects in endothelial cells. Indeed, adminis-
tration of PAF to rodents and activation of PAFR on endo-
thelial cells induces hypotension and increased vascular1958permeability.106,107 Therefore, an action of PAF on PAFR in
endothelial cells, promoting increased vascular permeability,
may contribute to the changes observed during DENV
infection in mice. Of note, the protection afforded by inhi-
bition of PAFR activation during dengue infection occurred
without loss of control of viral replication, and there was
signiﬁcant production of IFN-g in both PAFR/ and PAFR
antagonistetreated mice.67
Altogether these studies suggest that PAFR is a disease-
associated gene but not necessary for the murine host to
control dengue infection. Whether the ﬁndings translate into
a real therapy for severe cases of dengue still deserves further
investigation, but these results represent important proof-of-
concept for the idea that interfering with some inﬂammatory
mediators in the context of DENV infection may decrease
disease severity without impairing pathogen elimination.Conclusion
On DENV infection, the host must establish an appropriate
inﬂammatory response to clear the pathogen, thereby elim-
inating the risk of disease. Several innate and inﬂammatory
pathways activated at the early stages after DENV recog-
nition by host cells are essential for resistance to infection.
Some of these protective molecules identiﬁed so far include
the pathogen-recognition receptors TLR3, RIG-I, and MDA5
and antiviral type I and type II interferons produced on acti-
vation of the previous pathogen-recognition receptors. These
are only the ﬁrst molecules proven to provide protection from
DENV infection, and several others may have to be identiﬁed.
An appropriate inﬂammatory response requires that the
response is controlled in several aspects, including its character
(the type of mediators released or cells activated), intensity,
location, and duration. Decreased or absent response may lead
to parasite growth and disease. Of note, there is now evidence
that severe dengue disease manifestation is associated with
subversion of protective pathways by both viral and host
factors, suggesting that altered host responses are directly
involved in dengue disease severity. In addition, it appears that
excessive inﬂammation, whether during primary or secondary
cases of infection, contributes to the pathogenesis of severe
dengue disease. Therefore, it is possible that a decrease in the
productionof certain proinﬂammatorymoleculesmaydecrease
dengue-induced vascular leakage and disease severity. The
biggest challenge will be to determine appropriate targets
whose inhibition will result in inhibition of overt inﬂammation
and endothelial barrier permeability without interfering with
immune mechanisms involved in DENV clearance. Some
potential targets are Fc receptors, as well as some proin-
ﬂammatory cytokine and chemokines, including CCR2 and
CCR4 receptors.Moreover, PAFRblockade represents another
novel target to modulate the inﬂammatory response and
vascular leakage in dengue infection without impairment of
pathogen clearance. Because antiviral compounds may be
developed from drug screening, immune-modulating drugsajp.amjpathol.org - The American Journal of Pathology
Inﬂammatory Pathways in Dengue Diseasethat prevent severe disease may represent important adjunct
therapy for the treatment of severe dengue.
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